Cargando…

Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput in silico screening

Small molecules that bind with high affinity and specificity to fibrils of the α-synuclein (αS) protein have the potential to serve as positron emission tomography (PET) imaging probes to aid in the diagnosis of Parkinson's disease and related synucleinopathies. To identify such molecules, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrie, John J., Lengyel-Zhand, Zsofia, Janssen, Bieneke, Lougee, Marshall G., Giannakoulias, Sam, Hsieh, Chia-Ju, Pagar, Vinayak Vishnu, Weng, Chi-Chang, Xu, Hong, Graham, Thomas J. A., Lee, Virginia M.-Y., Mach, Robert H., Petersson, E. James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047729/
https://www.ncbi.nlm.nih.gov/pubmed/33889379
http://dx.doi.org/10.1039/d0sc02159h
Descripción
Sumario:Small molecules that bind with high affinity and specificity to fibrils of the α-synuclein (αS) protein have the potential to serve as positron emission tomography (PET) imaging probes to aid in the diagnosis of Parkinson's disease and related synucleinopathies. To identify such molecules, we employed an ultra-high throughput in silico screening strategy using idealized pseudo-ligands termed exemplars to identify compounds for experimental binding studies. For the top hit from this screen, we used photo-crosslinking to confirm its binding site and studied the structure–activity relationship of its analogs to develop multiple molecules with nanomolar affinity for αS fibrils and moderate specificity for αS over Aβ fibrils. Lastly, we demonstrated the potential of the lead analog as an imaging probe by measuring binding to αS-enriched homogenates from mouse brain tissue using a radiolabeled analog of the identified molecule. This study demonstrates the validity of our powerful new approach to the discovery of PET probes for challenging molecular targets.